South Korea · Delayed Price · Currency is KRW OliX Pharmaceuticals Company Description
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.
The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis.
The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia.
The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
| Country | South Korea |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dong-Ki Lee |
Contact Details
Address: Suite 1014 Suwon-si South Korea | |
| Phone | 82 3 1779 8400 |
| Website | olixpharma.com |
Stock Details
| Ticker Symbol | 226950 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7226950004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dong-Ki Lee | Chief Executive Officer |
| Jin Kim Young | Chief Financial Officer |